查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542857

全球肌腱病市场 - 2024-2031

Global Tendinopathy Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球肌腱病市场规模达2,152.6亿美元，预估至2031年将达2,991.6亿美元，2024-2031年预测期间复合年增长率为4.2%。

肌腱病变被定义为以疼痛、肿胀和功能受损为特征的肌腱退化。肌腱病变是指肌腱变得疼痛且活动范围有限。肌腱病比肌腱炎更常见，它可能由多种原因引起，例如老化、压力或受伤。

肌腱是将肌肉与骨头连接起来的绳索状组织。当肌腱受伤或过度使用时，就会出现肌腱病变。儘管肌腱病可能会变成慢性，但休息和物理治疗可能会改善症状。

市场动态：

司机

肌腱和运动相关损伤的发生率增加

全球肌腱病市场的需求是由多种因素所驱动的。肌腱病市场是由肌腱和运动相关损伤发生率的增加所推动的。这一趋势很大程度上归因于体育活动的增加、职业伤害和导致肌腱炎的生活方式的改变，特别是在运动员和老龄化人口中。

肌腱病的盛行率正在上升，有报告表明，每年有超过一百万名运动员遭受肌腱相关损伤，占运动伤害的很大一部分。随着人们越来越多地参与体育运动和体育活动，这一趋势进一步加剧，导致对有效治疗方案的需求更高。根据 Sage Journals 2023 年 9 月发表的文章，肌腱损伤是一种常见的临床问题，由过度使用、遗传倾向、撕裂或老化引起。全球每年发生超过 3000 万例肌腱损伤。

同样，2023 年，国家安全委员会表示，有 370 万人因运动和娱乐设备受伤而在急诊室接受治疗。同一消息来源称，2022 年运动和娱乐伤害增加了 12%，这凸显了活跃人群患肌腱炎的风险不断增加。 2023 年，运动和娱乐伤害将增加 2%。

此外，投资等行业策略的关键参与者更加关注肌腱病的治疗，这将推动该市场的成长。例如，2023 年2 月，格拉斯哥大学专门研究肌腱疾病的衍生公司Causeway Therapeutics 从投资者那里筹集了875 万英镑，用于对其先导化合物TenoMIRa 治疗外上髁炎（网球肘）进行国际2 期临床试验。

此外，2021 年 10 月，梅奥诊所物理医学和復健专家 Jeffrey S. Brault（DO）和 Jane Konidis（医学博士）讨论了两种针对腕管综合症和肌腱病的微创治疗方法。腕隧道鬆解和肌腱病变治疗的新方法。

限制

高治疗成本、与药物相关的风险和毒性、人们缺乏认识、有效治疗选择有限以及监管挑战等因素预计将阻碍市场。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 肌腱和运动相关损伤的发生率不断增加
      • 科技不断进步
    • 限制
      • 治疗费用高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：依条件类型

  • 跟腱炎
  • 髌腱炎
  • 肩袖肌腱炎
  • 冈上肌腱炎
  • 其他条件

第 7 章：透过治疗

  • 药品类型
    • 非类固醇抗发炎药
    • 皮质类固醇注射剂
  • 矫正器、夹板和支架
  • 其他的

第 8 章：按通路

  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Zimmer Biomet
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • 3M
  • Stryker
  • Smith+Nephew
  • Ossur
  • Merck & Co., Inc.
  • Pfizer Inc
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Abbott

第 12 章：附录

简介目录
Product Code: PH8584

Overview

The global tendinopathy market reached US$ 215.26 billion in 2023 and is expected to reach US$ 299.16 billion by 2031 growing with a CAGR of 4.2% during the forecast period 2024-2031.

Tendinopathy is defined as tendon degeneration characterized by pain, swelling, and impaired performance. Tendinopathy is when a tendon becomes painful and has a limited range of motion. More common than tendonitis, tendinopathy can be caused by many things, like aging, stress, or injury.

Tendons are rope-like tissues that connect your muscles to your bones. Tendinopathy can develop when you injure or overuse a tendon. Although tendinopathy can become chronic, rest and physical therapy will likely improve symptoms.

Market Dynamics: Drivers

Increasing incidence of tendon and sports-related injuries

The demand for the global tendinopathy market is driven by multiple factors. The tendinopathy market is driven by an increasing incidence of tendon and sports-related injuries. This trend is largely attributed to a rise in sports activities, occupational injuries, and lifestyle changes that contribute to tendonitis, particularly among athletes and the aging population.

The prevalence of tendinopathy is rising, with reports indicating that athletes experience over a million tendon-related injuries annually, accounting for a significant portion of sports injuries. This trend is further exacerbated by the growing participation in sports and physical activities, leading to a higher demand for effective treatment options. As per Sage Journals publication in September 2023, tendon injuries are a common clinical problem that results from overuse, genetic predisposition, tears, or aging. More than 30 million tendon injuries occur annually worldwide.

Similarly, in 2023, the National Safety Council, stated that 3.7 million people were treated in emergency departments for injuries involving sports and recreational equipment. The same source, reported a 12% increase in sports and recreational injuries in 2022, highlighting the growing risk of tendonitis among active individuals The activities most frequently associated with injuries are exercise, cycling, and basketball. Sports and recreational injuries increase by 2% in 2023.

Moreover, key players in the industry strategies such as investments and more focus on the treatment of tendinopathy that would propel this market growth. For instance, in February 2023, Causeway Therapeutics, a University of Glasgow spin-out specializing in tendon disease raised £8.75 million from investors to conduct an international Phase 2 clinical trial of its lead compound, TenoMIRa in lateral epicondylitis (tennis elbow).

Also, in October 2021, Mayo Clinic Physical Medicine and Rehabilitation specialists Jeffrey S. Brault, D.O., and Jane Konidis, M.D., discuss two minimally invasive treatments for carpal tunnel syndrome and tendinopathy. New approaches to carpal tunnel release and treatment of tendinopathy.

Restraints

Factors such as high treatment costs, risk & toxicity associated with the drugs, lack of awareness among people, limited effective treatment options, and regulatory challenges are expected to hamper the market.

Segment Analysis

The global tendinopathy market is segmented based on condition type, treatment, distribution channels, and region.

The achilles tendinitis segment accounted for approximately 43.3% of the global tendinopathy market share

The achilles tendinitis segment is expected to hold the largest market share over the forecast period. The rise in sports activities, particularly among younger populations, has led to a corresponding increase in Achilles tendinitis cases. As more individuals engage in high-impact sports, the risk of developing this condition rises significantly driving this segment growth in the market.

Treatment modalities for Achilles tendinitis have evolved, with non-invasive options such as physical therapy, shockwave therapy, and regenerative therapies like platelet-rich plasma (PRP) injections gaining popularity. These treatments are preferred due to their effectiveness and lower recovery times compared to surgical options help to drive this market growth.

Moreover, key players in the industry more focus on research studies, investments in tendinopathy treatment, and key developments propel this segment in the market. For instance, in July 2022, a recent study in Physical Therapy in Sport found significant differences in strength and other fitness factors in those with Achilles tendinopathy compared to those without the condition. In addition to seeing a physical therapist to address Achilles pain, experts suggest focusing on calf-strengthening exercises, assessing your running schedule, and doing cross-training activities.

Similarly, in January 2023, NIH funded Penn Medicine's Achilles tendon research center for nearly $8M. The new Penn Achilles Tendinopathy Center of Research Translation seeks to build insights that lead to better treatment of Achilles tendon injuries.

Also, in July 2023, the Isokinetic Football Medicine Conference held May 25-27 in London revealed significant improvement in professional athletes with Achilles tendon injuries using a treatment of bio-inductive and multi-fractioned hyaluronic acid (HA) injections.

Geographical Analysis

North America accounted for approximately 42.8% of the global tendinopathy market share

North America region is expected to hold the largest market share over the forecast period owing to the high incidence of sports & occupational injuries driving this market growth in the region. According to the Science Direct in 2024, every year, there are more than 32 million acute and chronic tendon and ligament injuries that occur in the United States.

Moreover, the rising incidence of an aging population, well-established healthcare infrastructure, government initiatives such as awareness programs, and key player investments would drive this market growth. For instance, in January 2023, Zimmer Biomet Holdings, Inc. announced that it had reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 million at closing and up to an additional $120 million subject to achieving future regulatory and commercial milestones over three years.

In addition, a major number of key player's presence and product launches & approvals would propel this market growth in this region. For instance, in May 2021, Pendopharm launched SportVis, the first and only hyaluronic acid injection treatment that is clinically demonstrated and approved by Health Canada to relieve pain and restore function in damaged tendons and ligaments.

Also, in September 2021, Stryker introduced the new Citrelock Tendon Fixation Device System, which is designed to enable fixation without causing damage to the tendon during placement. The new system consists of a tendon thread with a resorbable technology called Citregen.

Market Segmentation

By Condition Type

  • Achilles Tendinitis
  • Patellar Tendinitis
  • Rotator Cuff Tendinitis
  • Supraspinatus Tendonitis
  • Other Conditions

By Treatment

  • Drug Type
    • NSAIDs
    • Corticosteroid Injections
  • Orthotics, Splints and Braces
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • The rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the tendinopathy market include Zimmer Biomet, 3M, Stryker, Smith+Nephew, Ossur, Merck & Co., Inc., Pfizer Inc., GSK plc., Johnson & Johnson Services, Inc., and Abbott among others.

Key Developments

  • In November 2022, Camber Pharmaceuticals launched generic Naprosyn. It is used to relieve pain from various conditions such as headaches, muscle aches, tendonitis, dental pain, and menstrual cramps.
  • In May 2022, CoNextions Inc. announced the first patient treated with CoNextions TR tendon repair system, a revolutionary tendon repair implant.
  • In April 2022, Boehringer Ingelheim launched RenuTend a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses.
  • In July 2021, Ossur launched the new Rebound Post-Op Elbow Brace, a non-invasive, lightweight adjustable brace with intuitive design features intended to optimize the fitting experience for clinicians as well as ease-of-use for patients who are recovering from severe elbow injury or surgical procedures.

Why Purchase the Report?

  • To visualize the global tendinopathy market segmentation based on condition type, treatment, distribution channels, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the tendinopathy market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global tendinopathy market report would provide approximately 62 tables, 56 figures, and 183 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Condition Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Distribution Channels
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Tendon and Sports-related Injuries
      • 4.1.1.2. Growing Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Treatment Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Condition Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 6.1.2. Market Attractiveness Index, By Condition Type
  • 6.2. Achilles Tendinitis *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Patellar Tendinitis
  • 6.4. Rotator Cuff Tendinitis
  • 6.5. Supraspinatus Tendonitis
  • 6.6. Other Conditions

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Market Attractiveness Index, By Treatment
  • 7.2. Drug Type *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. NSAIDs
    • 7.2.4. Corticosteroid Injections
  • 7.3. Orthotics, Splints and Braces
  • 7.4. Others

8. By Distribution Channels

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 8.1.2. Market Attractiveness Index, By Distribution Channels
  • 8.2. Hospital Pharmacies *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Zimmer Biomet *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. 3M
  • 11.3. Stryker
  • 11.4. Smith+Nephew
  • 11.5. Ossur
  • 11.6. Merck & Co., Inc.
  • 11.7. Pfizer Inc
  • 11.8. GSK plc
  • 11.9. Johnson & Johnson Services, Inc.
  • 11.10. Abbott

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us